Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Return on Capital Employed data on record, last reported at 0.62% in Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 18.0% year-over-year to 0.62%; the TTM value through Sep 2025 reached 0.62%, down 18.0%, while the annual FY2024 figure was 0.53%, 6.0% up from the prior year.
  • Return on Capital Employed reached 0.62% in Q3 2025 per VRDN's latest filing, down from 0.42% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.33% in Q4 2022 and bottomed at 1.28% in Q2 2021.
  • Average Return on Capital Employed over 5 years is 0.62%, with a median of 0.49% recorded in 2022.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 115bps in 2021, then crashed -33bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 0.4% in 2021, then rose by 17bps to 0.33% in 2022, then plummeted by -100bps to 0.66% in 2023, then surged by 37bps to 0.42% in 2024, then crashed by -47bps to 0.62% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.62% in Q3 2025, 0.42% in Q4 2024, and 0.44% in Q3 2024.